MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova, Inc. is a clinical-stage ... and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance ... Read More

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in ...

April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical ... that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected ... Read More

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

PHOENIX was a 48-week, randomized, placebo-controlled, global Phase 3 clinical trial further evaluating ... pathogenic TDP-43 mutations. Progressive supranuclear palsy (PSP) is a sporadic, rare ... Read More

GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors

Patients enrolled in the ROADS clinical trial are randomized into ... Enrollment in the Phase 3 trial has now surpassed half of the 180 planned patients. They will be followed for up to three ... Read More

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

"Our comprehensive data analysis is ongoing, and upon completion, we plan to meet with the FDA to discuss and get feedback on the design of the next pivotal Phase 3 clinical trial. Furthermore ... Read More

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects ... placebo-controlled Phase 3 trial, evaluating the safety and efficacy ... Read More

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Topline results from the Phase 3 monotherapy trials for tavapadon, TEMPO-1 and TEMPO-2, are expected in the second half of 2024. About TEMPO Clinical ... This press release contains forward ... Read More

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability ... Read More

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive ... in clinical development. MediciNova’s lead ... Read More

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan | Morningstar

Morningstar brands and products Company Get 7 Days Free ... Read More